Group 1 - CytomX Therapeutics, Inc. has received an increased price target of $12 from Piper Sandler analyst Joseph Catanzaro, up from $10, while maintaining an Overweight rating due to positive Phase 1 clinical data for its lead drug candidate, varsetatug maseatecan (varseta-M) [1][2] - The Phase 1 clinical data showed a dose-dependent efficacy, with a 32% objective response rate and an 84% disease control rate at the 10mg/kg dose [2] - CytomX has initiated a Phase Ib study combining varseta-M with Avastin and plans to start a separate Phase Ib/II trial combining Avastin with chemotherapy for earlier-line colorectal cancer patients, indicating a strategic shift to move the drug up the treatment ladder [3] Group 2 - CytomX is preparing to present Phase 1 data on CX-801 combined with Merck's KEYTRUDA for advanced melanoma patients by the end of 2026, adding a second clinical catalyst to its pipeline [4] - The company ended 2025 with $137 million in cash and raised an additional $250 million through a stock offering, bringing pro forma cash to approximately $372 million, providing sufficient funding for ongoing and planned trials [5] - CytomX is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer treatment, utilizing its proprietary Probody technology to target tumor tissue while minimizing effects on healthy cells [6]

Company Overview - Genmab A/S is an international biotechnology company focused on improving the lives of individuals with cancer and other serious diseases through innovative antibody medicines [2] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [3] Product and Pipeline - Genmab has developed a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), and immune-modulating antibodies [2] - The company has eight approved antibody medicines and is advancing a strong late-stage clinical pipeline with the aim of delivering transformative medicines to patients [2] Upcoming Events - Genmab's CEO, Jan van de Winkel, will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:45 PM PST [1]

Core Viewpoint - Compass Therapeutics Inc. (NASDAQ:CMPX) is viewed positively by analysts due to significant advancements in its clinical pipeline, with price targets set at $12 and $24 by different analysts [1][2]. Company Developments - The company has made notable progress in its drug pipeline, particularly with the development of CTX-10726, a tetravalent antibody aimed at inhibiting tumor angiogenesis [2]. - During the third-quarter 2025 results, the CEO highlighted lower mortality rates in a randomized trial of tovecimig for patients with advanced biliary tract cancer (BTC) and anticipates delivering overall survival (OS) and progression-free survival (PFS) data in the first quarter of the next year [3]. - The company expects to support its first Biologics License Application (BLA) filing in the second half of 2026, based on secondary endpoint data that builds on previously reported primary endpoint results [4]. Market Potential - Recent market research indicates approximately 25,000 new BTC diagnoses annually in the United States, suggesting a significant market opportunity for tovecimig, especially for patients lacking approved therapeutic options [4]. Financial Performance - The company reported a net loss of $14.3 million, or $0.08 per share, which is an increase from a net loss of $10.5 million in the same quarter the previous year. This wider loss is attributed to increased research and development expenses, which rose to $12.8 million from $8.6 million year-over-year [5]. Company Overview - Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapies for cancer, emphasizing the interplay between angiogenesis, the immune system, and tumor growth [6].